Similarly, the effect of novel therapeutic agents like sacubitril/valsartan and sodium/glucose cotransporter-2 inhibitors (SGLT2i), which have shown promise in altering the course of conditions such as heart failure and diabetes mellitus, was not thoroughly documented in our study [15]. Here, SLC5A2 is linked to heart failure.